Tim Funnell
Founder at Monograph Capital Advisors (UK) LLP
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Travis Murdoch | M | - |
University of Oxford
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB.
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 7 years |
John McCafferty | M | 66 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 years |
Chris E. Shaw | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Timothy Funnell | M | 38 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 3 years |
Aneesh Karatt-Vellatt | M | 37 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 years |
Fred Cohen | M | 67 |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
Luke Pike | M | - |
University of Oxford
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 7 years |
Dear Freddie | M | - |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021.
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
Eliot Charles | M | 62 |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | 5 years |
Youn Bok Lee | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Lisa Deschamps | F | 52 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Bonnie van Wilgenburg | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB.
University of Oxford
| 8 years |
Michael LaGatta | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 1 years |
Graeme Fielder | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 4 years |
Nishat Miah | F | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB.
University of Oxford
| 8 years |
Charles Conn | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
Nihal Sinha | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.
University of Cambridge
| 4 years |
Fred Cohen | M | 68 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | - |
Arnav Mehta | M | - |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 7 years |
Do Young Lee | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Stephanie Fox | F | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 1 years |
Michael Charles Beecham | M | 36 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
Balaji Muralidhar | M | 45 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
Eric Norio Shiozaki | M | 47 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
Jaideep Dudani | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
Robert Black | M | 65 |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 12 years |
Lucy Edwardes Jones | F | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
Amber Salzman | M | 62 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Hitesh Thakrar | M | 62 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 8 years |
J. Goater | M | 48 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 1 years |
Thomas Weaver | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | - |
Marc Feldmann | M | 79 |
University of Oxford
| 13 years |
Eva-Lotta Allan | F | 65 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
Raj Ganguly | M | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 11 years |
Ngaire Woods | F | 62 |
University of Oxford
| 14 years |
Laurence Barker | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Matthew McAviney | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
Andrey Kozlov | M | 48 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
Sohaib Mir | M | 42 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 years |
Nikki Padden | F | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 10 years |
Lai Kuen Louey | M | 64 |
University of Oxford
| 13 years |
Mike Stella | M | - |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James Cust | M | - |
University of Cambridge
University of Oxford
| 11 years |
James Sullivan Smith | M | - |
University of Cambridge
University of Oxford
| 6 years |
Mark Zaleski | M | - |
University of Oxford
| 1 years |
Cristina Escoda | M | - |
University of Cambridge
| 6 years |
Tom Joy | M | - |
University of Oxford
| 4 years |
Deviyani Godwin | M | - |
University of Cambridge
| 4 years |
Andrew James Mclean | M | 39 |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom.
University of Oxford
| 5 years |
Rabeel Warraich | M | - |
University of Oxford
| 4 years |
Nancy Xu | F | - |
University of Cambridge
| 3 years |
Brendan Baker | M | - |
University of Oxford
University of Cambridge
| 3 years |
Hon Wah Ip | M | 42 |
University of Cambridge
| 5 years |
Fraser Johnston-Donne | M | - |
University of Cambridge
| 4 years |
Terese Hougaard | F | - |
University of Cambridge
| 3 years |
John Lee Allen | M | - |
University of Oxford
| 15 years |
Galya Blachman | M | 47 |
University of Oxford
University of Cambridge
| 5 years |
Ian Hogarth | M | - |
University of Cambridge
| 3 years |
Abinand Rangesh | M | 39 |
University of Cambridge
| 8 years |
Dun Xiao | M | 38 |
University of Cambridge
| 5 years |
Elwyn Davies | M | - |
University of Oxford
| 3 years |
Gaurav Nayyar | M | - |
University of Cambridge
University of Oxford
| 7 years |
TAM EMILY | F | - |
University of Cambridge
| 3 years |
Matthew Powell | M | - |
University of Oxford
| 5 years |
Joe Hepplewhite | M | - |
University of Oxford
| 5 years |
Alex Hood | M | - |
University of Oxford
| 4 years |
de Vere Max | M | - |
University of Oxford
| 4 years |
Kim Powell | F | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 10 years |
Kai Yu Liu | M | 39 |
University of Oxford
| 4 years |
Charles Kok Hoong Chwan | M | - |
University of Cambridge
| 4 years |
Marco Francescon | M | - |
University of Oxford
| 4 years |
Sarah Larson | F | - |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | 3 years |
Philip Cowans | M | - |
University of Cambridge
| 8 years |
Sanjeet Mangat | F | - |
University of Cambridge
| 2 years |
Jonathan Ma | M | - |
University of Cambridge
| 4 years |
Timothy Blomfield | M | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 7 years |
Timothy David Short | M | 43 |
University of Cambridge
| 5 years |
Amy Heineike | F | - |
University of Cambridge
| 3 years |
Tun Lin | M | 50 |
University of Cambridge
| 4 years |
Alexander Semenovich Vinokurov | M | 41 |
University of Cambridge
| 5 years |
Piotr Krupa | M | - |
University of Cambridge
| 6 years |
Chad Frischmann | M | - |
University of Oxford
| 5 years |
Blake Carmen Clayton | M | - |
University of Cambridge
University of Oxford
| 5 years |
John Ettinger | M | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 3 years |
Kai Lin | M | - |
University of Cambridge
| 4 years |
Daniel McBee | M | - |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | 3 years |
Dominic Schmidt | M | 42 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.
University of Cambridge
| 13 years |
Inga Deakin | M | - |
University of Cambridge
University of Oxford
| 8 years |
Harry Simpson | M | - |
University of Cambridge
| 4 years |
Akhil Paul | M | 39 |
University of Oxford
| 4 years |
Edward Lunken | M | - |
University of Oxford
University of Cambridge
| 5 years |
Michael Zhang | M | - |
University of Cambridge
| 4 years |
Sarah McDowall | F | - |
University of Cambridge
| 4 years |
Oscar Hutchinson | M | - |
University of Oxford
| 3 years |
Jessica Ferm | F | - |
University of Cambridge
| 4 years |
Amol Pawar | M | - |
University of Cambridge
| 4 years |
Ritika Chandra | F | - |
University of Cambridge
| 3 years |
Therese Niklasson | F | - |
University of Oxford
| 2 years |
Robert Jonathan Klaber | M | - |
University of Cambridge
| 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 92 | 92.00% |
United States | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Tim Funnell
- Personal Network